Comparative Efficacy of Ceritinib and Crizotinib as Initial ALK–Targeted Therapies in Previously Treated Advanced NSCLC: An Adjusted Comparison with External Controls

[1]  G. Scagliotti,et al.  ASCEND-3: A single-arm, open-label, multicenter phase II study of ceritinib in ALKi-naïve adult patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC). , 2015 .

[2]  J. Engelman,et al.  Progression-Free and Overall Survival in ALK-Positive NSCLC Patients Treated with Sequential Crizotinib and Ceritinib , 2015, Clinical Cancer Research.

[3]  F. Cappuzzo,et al.  First-line crizotinib versus chemotherapy in ALK-positive lung cancer. , 2014, The New England journal of medicine.

[4]  A. Shaw,et al.  1295PEFFICACY AND SAFETY OF CERITINIB IN PATIENTS (PTS) WITH ADVANCED ANAPLASTIC LYMPHOMA KINASE (ALK)-REARRANGED (ALK+) NON-SMALL CELL LUNG CANCER (NSCLC): AN UPDATE OF ASCEND-1. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  Roman K. Thomas.  Overcoming drug resistance in ALK-rearranged lung cancer. , 2014, The New England journal of medicine.

[6]  J. Engelman,et al.  Ceritinib in ALK-rearranged non-small-cell lung cancer. , 2014, The New England journal of medicine.

[7]  Jae Ho Lee,et al.  Comparison of clinical characteristics between patients with ALK-positive and EGFR-positive lung adenocarcinoma. , 2014, Respiratory medicine.

[8]  Michael Thomas,et al.  Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. , 2013, The New England journal of medicine.

[9]  N. Latimer.  Survival Analysis for Economic Evaluations Alongside Clinical Trials—Extrapolation with Patient-Level Data , 2013, Medical decision making.

[10]  Jeffrey W. Clark,et al.  Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. , 2012, The Lancet. Oncology.

[11]  S. Barni,et al.  Biological agents alone or in combination as second-line therapy in advanced non-small-cell lung cancer: systematic review of randomized studies , 2012, Expert review of anticancer therapy.

[12]  Mei Lu,et al.  Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research. , 2012, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[13]  A. Shaw,et al.  Results of a global phase II study with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC). , 2012 .

[14]  Mei Lu,et al.  Comparative effectiveness research using matching‐adjusted indirect comparison: an application to treatment with guanfacine extended release or atomoxetine in children with attention‐deficit/hyperactivity disorder and comorbid oppositional defiant disorder , 2012, Pharmacoepidemiology and drug safety.

[15]  M. Socinski,et al.  Personalized therapy for non-small cell lung cancer: which drug for which patient? , 2011, Seminars in thoracic and cardiovascular surgery.

[16]  Jeffrey W. Clark,et al.  Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. , 2011, The Lancet. Oncology.

[17]  J. Börgermann,et al.  Treatments effects from randomized trials and propensity score analyses were similar in similar populations in an example from cardiac surgery. , 2011, Journal of clinical epidemiology.

[18]  Zhimei Liu,et al.  An adjusted indirect comparison of everolimus and sorafenib therapy in sunitinib-refractory metastatic renal cell carcinoma patients using repeated matched samples , 2011, Expert opinion on pharmacotherapy.

[19]  D. DeAngelo,et al.  Comparative efficacy of nilotinib and dasatinib in newly diagnosed chronic myeloid leukemia: a matching-adjusted indirect comparison of randomized trials , 2011, Current medical research and opinion.

[20]  Ryohei Katayama,et al.  Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK , 2011, Proceedings of the National Academy of Sciences.

[21]  Qinghua Zhou,et al.  Comparisons between the National Comprehensive Cancer Network (NCCN) non‐small‐cell lung cancer (NSCLC) Clinical Practice Guidelines (Chinese version), the NCCN original edition, and the European Society for Medical Oncology NSCLC Guidelines in 2009 , 2010, Thoracic cancer.

[22]  A. Iafrate,et al.  Unique Clinicopathologic Features Characterize ALK-Rearranged Lung Adenocarcinoma in the Western Population , 2009, Clinical Cancer Research.

[23]  A. Jemal,et al.  Cancer Statistics, 2009 , 2009, CA: a cancer journal for clinicians.

[24]  Derek Y. Chiang,et al.  EML4-ALK Fusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung Cancer , 2008, Clinical Cancer Research.

[25]  M. Socinski,et al.  Treatment of non-small cell lung cancer, stage IV: ACCP evidence-based clinical practice guidelines (2nd edition). , 2007, Chest.

[26]  M. Socinski,et al.  Third-Generation Chemotherapy Agents in the Treatment of Advanced Non-small Cell Lung Cancer: A Meta-Analysis , 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[27]  D. Esseltine,et al.  Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study. , 2006, Blood.

[28]  G. Imbens,et al.  Estimation of Causal Effects using Propensity Score Weighting: An Application to Data on Right Heart Catheterization , 2001, Health Services and Outcomes Research Methodology.

[29]  Hodgkin Lymphoma.  NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines , 2014 .

[30]  Eric Q. Wu,et al.  Comparative Effectiveness Without Head-to-Head Trials , 2012, PharmacoEconomics.

[31]  R. Hubbard,et al.  Effect of statins on a wide range of health outcomes: a cohort study validated by comparison with randomized trials. , 2009, British journal of clinical pharmacology.

[32]  D. Rubin,et al.  Matched Sampling for Causal Effects: The Central Role of the Propensity Score in Observational Studies for Causal Effects , 2006 .

[33]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[34]  F. Duffy,et al.  T E C H N I C a L a D V a N C E Open Access , 2022 .